MedTrace Logo

The Effects of a Synbiotic Addition on Eradication Therapy of Helicobacter Pylori Infection in Children

NCT03165253 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-05-24

No results posted yet for this study

Summary

The aim of the study is to evaluate the effects of the synbiotic Bifidobacterium animalis ssp. lactis B94 plus inulin addition to the standard triple therapy on Helicobacter pylori infection eradication rates in children.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Bifidobacterium Animalis Oral Product

The synbiotic group will receive this product.

DRUG

Amoxicillin Oral Tablet

50mg/kg/day B.I.D.

DRUG

Clarithromycin Oral Tablet

15 mg/kg/day B.I.D.

DRUG

Omeprazole

1 mg/kg/day

Sponsors & Collaborators

  • Bulent Ecevit University

    lead OTHER

Principal Investigators

  • Gonca H Ustundag, MD · Associate professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-06-30
Completion
2012-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03165253 on ClinicalTrials.gov